Allison DeAngelis from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago STAT+: With big ambition — and a family name to match — Reed Jobs charts his own course in biotech - 5 months ago STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator - 6 months ago STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down - 6 months ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - 6 months ago Listen: A CRISPR milestone, algorithms amok, & biotech mixology - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago STAT+: Biotech incubator Curie.Bio graduates its first startup - 6 months ago STAT+: In the fight against cancer, it’s boom times for radiopharmaceuticals - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago STAT+: Life science investors close nearly $6 billion in new funds - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago STAT+: Startup Laronde merges with another biotech in wake of data integrity issue - 7 months ago STAT+: Dana-Farber executive says split from Mass General will benefit patients - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago STAT+: Life sciences deals on track to hit lowest point since 2017 - 7 months ago STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug - 8 months ago Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus - 8 months ago STAT+: What ever happened to biotech’s big comeback? - 8 months ago A thorny ALS debate at the FDA, and the promise of artificial wombs - 8 months ago
2	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus - 8 months ago STAT+: What ever happened to biotech’s big comeback? - 8 months ago A thorny ALS debate at the FDA, and the promise of artificial wombs - 8 months ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: A CRISPR milestone, algorithms amok, & biotech mixology - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 5 months ago
5	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - 6 months ago